BECTON DICKINSON & CO
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BD (BDX) announced its STANCE clinical trial for GalaFLEX LITE™ Scaffold in breast revision surgery has treated 274 patients, surpassing a key milestone. The trial, comparing the scaffold to conventional surgery, aims to support a future FDA application for a new breast indication. BD's P4HB technology has over a decade of clinical use in soft tissue support.
Becton, Dickinson and Co. (BD) launched a noninvasive continuous blood pressure monitoring system, the HemoSphere Stream Module. Tim Patz, BD's Worldwide President of Advanced Patient Monitoring, discussed the future of medtech monitoring, emphasizing the shift towards continuous, noninvasive solutions. BD's pipeline is 95% focused on noninvasive, continuous products, with a focus on high-acuity patients and FDA partnerships. The company has developed AI algorithms for early problem identificati
Becton, Dickinson and Company (BDX) completed enrollment for its PREVENT trial evaluating Phasix Mesh for preventing incisional hernias. The trial enrolled 477 patients and could support an FDA submission, expanding BDX's advanced tissue regeneration platform. BDX shares have traded flat year-to-date, with a market cap of $51.69 billion. Management views this as a long-term growth catalyst.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BDX (BECTON DICKINSON & CO). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent BDX coverage spans technology, earnings and insider activity.
In the last 30 days, BDX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($8.5M). The most active reporter was Polen Thomas E Jr, Chairman, CEO and President, with 2 filings. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive clinical progress may boost investor confidence in BD's tissue regeneration portfolio and support future FDA PMA filing.
Potential revenue uplift from a novel medtech product and expanded AI algorithm portfolio.
Enrollment completion may lead to future FDA submission and potential market expansion.
Leadership change in BD’s quality function could shift internal quality priorities and execution cadence, but no new quality metrics or regulatory outcomes are disclosed.
The article combines a fresh earnings beat and explicit full-year EPS guidance with a bullish analyst stance and price-target upside, supporting near-term sentiment and positioning.
alphai scores every news story that mentions BDX with an AI model for sentiment and relevance, and aggregates insider trades from BECTON DICKINSON & CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
BD (BDX) announced its STANCE clinical trial for GalaFLEX LITE™ Scaffold in breast revision surgery has treated 274 patients, surpassing a key milestone. The trial, comparing the scaffold to conventional surgery, aims to support a future FDA application for a new breast indication. BD's P4HB technology has over a decade of clinical use in soft tissue support.
2 min readBecton, Dickinson and Co. (BD) launched a noninvasive continuous blood pressure monitoring system, the HemoSphere Stream Module. Tim Patz, BD's Worldwide President of Advanced Patient Monitoring, discussed the future of medtech monitoring, emphasizing the shift towards continuous, noninvasive solutions. BD's pipeline is 95% focused on noninvasive, continuous products, with a focus on high-acuity patients and FDA partnerships. The company has developed AI algorithms for early problem identificati
2 min readBecton, Dickinson and Company (BDX) completed enrollment for its PREVENT trial evaluating Phasix Mesh for preventing incisional hernias. The trial enrolled 477 patients and could support an FDA submission, expanding BDX's advanced tissue regeneration platform. BDX shares have traded flat year-to-date, with a market cap of $51.69 billion. Management views this as a long-term growth catalyst.
2 min readBD (NYSE: BDX) said Gary Sorsher will become executive vice president and chief quality officer effective Sept. 8. He previously served as chief quality officer at Edwards Lifesciences. BD also announced Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years at the company.
2 min readBecton, Dickinson and Company (BDX) medical technology shares have outperformed the S&P 500 and the iShares U.S. Medical Devices ETF over the past year and YTD. After Q3 results on Aug. 6, BDX reported adjusted EPS of $3.23 vs $3.14 expected, revenue of $5.0B vs $4.9B, and full-year adjusted EPS guidance of $12.62 to $12.72. Analysts rate it a “Moderate Buy” with a mean target of $187.33 and a Citigroup target of $208.
3 min readPolen Thomas E Jr (Chairman, CEO and President) sold 4,152 shares of BECTON DICKINSON & CO (BDX) at $185.00 ($0.77M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
2 min readPolen Thomas E Jr (Chairman, CEO and President) sold (to issuer) 39,126 shares of BECTON DICKINSON & CO (BDX) at $185.00 ($7.24M total) on 2026-08-13 under a Rule 10b5-1 trading plan.
1 min readThe article reviews post-earnings outlooks for four “Dividend Kings”: Becton Dickinson (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH). It cites quarterly results, cash flow, and updated FY26 guidance. BDX reported Q3 adjusted EPS $3.23 vs $3.14, ED Q2 EPS 83c vs 74c, EMR Q3 EPS $1.71 vs $1.68, and PH FY4 EPS $9.27 vs $8.29.
7 min readMedline said regulatory guidance followed its corrective actions for surgical convenience kits whose components were affected by a Becton Dickinson recall. The alert cites BD lot 4032183 ChloraPrep Clear 1 mL and lot 4073005 FREPP Clear 1.5 mL applicators, with compromised sterile seals and possible Aspergillus contamination. Medline reported no severe injuries or deaths as of Aug 3. MDLN shares were $35.71, up 0.61%.
4 min readBD reported Q3 fiscal 2026 results for “New BD” after its Life Sciences spin-off. Revenue was $4.98B, up 4.4% FX-neutral; adjusted diluted EPS was $3.23, up 4.9%. Adjusted operating margin was 24.9% after 110 bps tariff impact. Full-year adjusted EPS guidance raised to $12.62-$12.72 midpoint; revenue growth guided toward high end of low-single-digit FX-neutral range.
6 min read
%252FBD%252520Canada's%252520head%252520office%252520building%252520in%252520Mississauga%25252C%252520On%25252C%252520Canada_%252520%252520By%252520JHVEPhoto.jpeg&w=3840&q=75)
